Catalog No: CFN99952

Daphnetin is a dihydroxycoumarin that is being used in China for the treatment of coagulation disorders, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit antimalarial, anti-rheumatoid arthritis, anti-proliferative, anti-inflammatory and anti-oxidant activities. it is also a chelator and an antioxidant. Daphnetin can enhance immunological functions of B lymphocytes, the expression of IL-12 in B lymphocytes can be up-regulated by daphnetin through natural immunity approach.
alpha-Amyrin palmitate
Catalog No: CFN98210

alpha-Amyrin palmitate is antiarthritic in the adjuvant model of arthritis in rats. alpha-Amyrin palmitate is a potent non-competitive inhibitor of chymotrypsin (Ki=6 microM), it also shows weak cytotoxicity against the A2780 human ovarian cancer cell line.
Catalog No: CFN98371

Astilbin has insecticidal, antioxidant, antibacterial, and anti-inflammatory activities, it may act as an efficient therapeutic agent for arthritis like cyclosporine A but with less toxicity, its mechanism includes a selective suppression on lymphocyte functions via reducing MMP and NO production. Astilbin can exert an early renal protective role to diabetic nephropathy (DN), inhibit production of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF).Astilbin also alleviates contact hypersensitivity through a unique mechanism involving a negative cytokine regulation through stimulating IL-10, which is distinct from the immunosuppressant cyclosporin A.
Catalog No: CFN98724

Bergenin is a potent antinarcotic agent, has antiviral ,antifungal, antiarrhythmic, antitumor, antiinflammatory, potent immunomodulatory, antitussive, antiulcerogenic,anti-plasmodial, anti-hepatotoxic and wound healing activities. Bergenin has antidiabetic activity, could be classified as a new group of α-glucosidase inhibitors. Bergenin reduces the expression of NO, TNF-α, IL-1β, and IL-6 proinflammatory cytokines by inhibiting the activation of the NF-κB and MAPKs signaling pathways, and it may represent a novel treatment strategy for mastitis.
Catalog No: CFN98867

Kirenol possesses anti-bacteria, immunosuppression, anti-obesity, anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation; it can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells. Kirenol activates the BMP and Wnt/β-catenin signaling pathways.